Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Micron | Flex | Pfizer | |
|---|---|---|---|
| Moat rating | narrow Micron sits in a three-firm DRAM oligopoly (with Samsung and SK hynix), holds "over 60,000 patents" and leading-edge process technology (industry-first 1-gamma EUV DRAM node in FY2025), yet its FY2025 10-K concedes competitors "may use aggressive pricing" and "may have a larger market share," and consolidated gross margin swung from negative 9% (FY2023) to 40% (FY2025) — a real but commodity-cyclical, non-durable advantage. | none The FY2026 10-K (fiscal year ended March 31, 2026) concedes the core business is contested on every side: "Our industry is extremely competitive, many of our competitors have achieved substantial market share, and some may have lower cost structures or greater design, manufacturing, financial or other resources than we do." Customers "could in the future decide to in-source, dual-source, regionalize, or otherwise reallocate manufacturing volumes among suppliers", certain contracts "permit the customer to terminate the agreement for convenience upon prior written notice", and hyperscale customers "typically have substantial purchasing power and negotiating leverage". TradingPilot's stored fundamentals (SEC XBRL) show gross profit of $1,976 million on net sales of $28,502 million in fiscal 2023 and $2,567 million on $27,914 million in fiscal 2026: a thin margin, even after widening. The Cloud and Power Infrastructure (CPI) segment sells its own power and cooling products, but the 10-K says it must keep offering "significant price and/or performance advantages over competitive products", and Flex intends to separate it into an independent company targeted for the first quarter of calendar 2027. A large contract manufacturer whose own filing describes no protected position: no moat is claimable. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip The 10-K roots Micron's edge in proprietary technology and IP: "over 60,000 patents" granted as of Aug 28, 2025, "significant investments to develop proprietary product and process technology," the industry's first 1-gamma (EUV) DRAM node, ninth-generation G9 NAND, and HBM4 samples to key AI customers. | none The 10-K's competitive strengths are operating capabilities, not a durable barrier: "Global Scale and Regional Strength" (more than 100 facilities across approximately 30 countries, staffed by approximately 150,000 employees), "Long-Standing, Diverse Customer Relationships", "Cross-Industry Synergies" and cost-efficient industrial parks. On intellectual property it says "we do not consider any single patent, trademark, or license to be material to our business as a whole" and that the carrying value of its intellectual property "was not material". Switching costs are limited by short commitments: "We generally do not obtain firm, long-term purchase commitments from our customers", and termination-for-convenience notice periods "may be relatively short". | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | co leader A member of the three-supplier DRAM oligopoly and at the technology frontier (industry-first 1-gamma EUV node), but the smallest of the three by share — the 10-K acknowledges competitors "may have a larger market share" — and a later entrant scaling up in HBM behind SK hynix and Samsung. | at parity EMSNOW/in4ma's "EMS&ODM Global 100" (2026-03-06, https://www.emsnow.com/?p=53535) says Wistron, Quanta and Wiwynn "plus Foxconn together account for nearly 57% of global EMS/ODM production", and groups Flex with Jabil, Celestica and Sanmina as the US "big four", "representing about 85% of the revenue base among ~20 US headquartered EMS/ODM". The FY2026 10-K claims no rank and says "many of our competitors have achieved substantial market share". One of a handful of large Western contract manufacturers, behind the Taiwanese leaders in scale: at parity with its peer group, not a leader. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | weak Memory is a commodity with cyclical ASPs: the 10-K flags "volatility in average selling prices" and competitors' "aggressive pricing" as key risks, and consolidated gross margin swung from -9% (FY2023) to 22% (FY2024) to 40% (FY2025), marking Micron largely as a cyclical price-taker; contract-based, supply-tight HBM is a partial exception. | weak Stored fundamentals show gross profit of $1,976 million on $28,502 million of net sales in fiscal 2023 and $2,567 million on $27,914 million in fiscal 2026; on the Q1 FY2027 call (https://earningswhispers.com/transcript/FLEX/Q12027) the CFO said adjusted gross margin "improved to 9.6%, up 50 basis points from the prior year". The 10-K sets the limits: hyperscale customers have "substantial purchasing power and negotiating leverage, which they may use to obtain favorable pricing, extended payment terms, volume flexibility, or other concessions that could reduce our margins", and if CPI's competitors "adopt innovations more quickly or develop superior products, our win rates, pricing, and margins may suffer". | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Micron is one of only three scaled DRAM suppliers (with Samsung and SK hynix) and a leading-edge NAND maker, defended by proprietary product and process technology and more than 60,000 granted patents. In FY2025 it shipped the industry's first 1-gamma (EUV) DRAM production node and sampled HBM4 36GB 12-high to multiple key customers for next-generation AI platforms, evidencing process-technology leadership in AI memory (FY2025 10-K). | Flex designs, builds and manages products for other companies through, per its FY2026 10-K, three segments: Integrated Technology Solutions (communications, enterprise and lifestyle products), Regulated Manufacturing Solutions (industrial, automotive and healthcare) and Cloud and Power Infrastructure (integrated compute systems, liquid cooling, and utility-, facility-, rack- and board-level power). It runs more than 100 facilities in approximately 30 countries; its ten largest customers were 45% of fiscal 2026 net sales and none exceeded 10%. The data-centre business is the growth engine: on the Q1 FY2027 call (2026-07-29) the CFO said CPI revenue "totaled $2.2 billion, up 35% from the prior year, driven by strong growth in power", at a 9.7% adjusted operating margin, against 5.2% for ITS and 6.6% for RMS. Flex plans to spin CPI off as Axiom in the first quarter of calendar 2027, after funds affiliated with General Catalyst, Koch Equity Development and co-investors agreed a $2.0 billion convertible preferred investment "at an initial enterprise value for Axiom of $37.5 billion" (Flex release, 2026-10-05: https://www.sec.gov/Archives/edgar/data/866374/000119312526413173/d123485dex991.htm). The filing itself describes no durable barrier: the industry is "extremely competitive", rivals including Taiwanese ODM suppliers "in some cases, have a substantial share of global information technology hardware and related infrastructure production", customers can in-source or reallocate volume, and hyperscalers can use their leverage "to obtain favorable pricing". An independent tally (EMSNOW/in4ma, 2026-03-06) puts Foxconn, Wistron, Quanta and Wiwynn at "nearly 57% of global EMS/ODM production" and counts Flex among the US "big four". Scale plus a fast-growing power franchise that is about to leave the group, but no moat. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | US-based supplier of the memory tier of the AI stack — DRAM, HBM and NAND; the 10-K notes cloud servers for AI and data-centric workloads "require significantly increasing quantities of DRAM, including HBM," and Micron sampled HBM4 to power next-generation AI platforms. | Contract designer-manufacturer across many end markets and, through CPI, a supplier of power, cooling and rack-level compute infrastructure to "a limited number of hyperscale cloud providers, colocation companies, and large enterprise data center operators" (10-K), which Flex plans to separate as Axiom in the first quarter of calendar 2027. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.05 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |